Lumos FebriDx Mode D'emploi page 67

REFERENCES / BIBLIOGRAPHIE / LITERATUUR / BIBLIOGRAFIA / LITERATUR / REFERENCIAS / BIBLIOGRAFIA / ΒΙΒΛΙΟΓΡΑΦΙΑ
1. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory
tract infection in adults: advice for high-value care from the American College of
Physicians and the Centers for Disease Control and Prevention. Annals of Internal
Medicine 2016;164:425-34.
2. O'Neill J. Tackling drug-resistant infections globally: final report and
recommendations: Review on antimicrobial resistance; 2016.
3. Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host
response point-of-care test in patients hospitalised with suspected COVID-19.
Journal of Infection 2020.
4. Karim N, Ashraf MZ, Naeem M, et al. Utility of the FebriDx point-of-care test for
rapid triage and identification of possible coronavirus disease 2019 (COVID-19).
Int J Clin Pract. 2020.
5. Nakabayashi M, Adachi Y, Itazawa T, et al. MxA-based recognition of viral illness in
febrile children by a whole blood assay. Pediatric research 2006;60:770-4.
6. Itazawa T, Adachi Y, Imamura H, et al. Increased lymphoid MxA expression in acute
asthma exacerbation in children. Allergy 2001;56:895-8.
7. Forster J, Schweizer M, Schumacher RF, Kaufmehl K, Lob S. MxA protein in infants
and children with respiratory tract infection. Acta Paediatrica (Oslo, Norway : 1992)
1996;85:163-7.
8. Engelmann I, Dubos F, Lobert P-E, et al. Diagnosis of viral infections using
myxovirus resistance protein A (MxA). Pediatrics 2015;135:e985-e93.
9. Halminen M, Ilonen J, Julkunen I, Ruuskanen O, Simell O, Makela MJ. Expression
of MxA protein in blood lymphocytes discriminates between viral and bacterial
infections in febrile children. Pediatric research 1997;41:647-50.
10. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care
immunoassay to identify viral and/or bacterial immune response in patients
with acute febrile respiratory infection. European clinical respiratory journal
2015;2:28245.
11. Andreola B, Bressan S, Callegaro S, Liverani A, Plebani M, Da Dalt L. Procalcitonin
and C-reactive protein as diagnostic markers of severe bacterial infections in
febrile infants and children in the emergency department. The Pediatric infectious
disease journal 2007;26:672-7.
12. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and
C-reactive protein levels as markers of bacterial infection: a systematic review and
meta-analysis. Clinical infectious diseases: an official publication of the Infectious
Diseases Society of America 2004;39:206-17.
13. Halminen M, Ilonen J, Julkunen I, Ruuskanen O, Simell O, Mäkelä MJ. Expression
of MxA protein in blood lymphocytes discriminates between viral and bacterial
infections in febrile children. Pediatric research 1997;41:647.
14. Salonen EM, Vaheri A. C-reactive protein in acute viral infections. Journal of
medical virology 1981;8:161-7.
15. Chew, Keng Sheng. "What's new in Emergencies Trauma and Shock? C-reactive
protein as a potential clinical biomarker for influenza infection: More questions
than answers." Journal of emergencies, trauma, and shock 5.2 (2012):115.
16. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to
determine accuracy of FebriDx point-of-care testing for acute upper respiratory
infections with and without a confirmed fever. Annals of medicine 2018;50:420-9.
17. Self WH, Rosen J, Sharp SC, et al. Diagnostic accuracy of FebriDx: a rapid test
to detect immune responses to viral and bacterial upper respiratory infections.
Journal of clinical medicine 2017;6:94.
18. Davidson M. FebriDx Point-of-Care Testing to Guide Antibiotic Therapy for Acute
Respiratory Tract Infection in UK Primary Care: A Retrospective Outcome Analysis.
J Infect Dis Preve Med 2017;5:165.
19. Lumos Diagnostics internal data, 2019.
20. The Centre for Disease Prevention and Control (ECDC). Case definition
for coronavirus disease 2019 (COVID-19), as of 29 May 2020. Available at:
https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition2020.
21. The Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019
(COVID-19): 2020 Interim Case Definition, Approved April 5, 2020 2020. Available at:
https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-
definition/2020/.)
22. Food and Drug Administration (FDA). Assay Migration Studies for In Vitro
Diagnostic Devices: Guidance for Industry and FDA Staff. April 25, 2013:1-47.
Available at: https://www.fda.gov/media/73669/download.
67